Table 3.
A list of selected ongoing Ewing’s sarcoma trials (from clinicaltrials.gov, accessed on 06/10/2014)
| Study Drugs | Phase |
clinicaltrial.org identifier |
Sponsor/lead organizations |
Targeted molecule |
Number of recruites |
|---|---|---|---|---|---|
|
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) |
II | NCT01492673 | Memorial Sloan- Kettering Cancer Center |
VEGFR | 29 |
| Dasatinib | II | NCT00464620 | Sarcoma Alliance for Research through Colloboration |
KIT | 502 |
| Dasatinib and ipilimumab | I | NCT01643278 | National Cancer Institute |
KIT, CTLA-4 | 30 |
| Regorafenib | II | NCT02048371 | Sarcoma Alliance for Research through Collaboration |
RTKs | 126 |
| Aflac ST0901 CHOANOME - Sirolimus | I | NCT01331135 | Emory University | mTOR | 24 |
| CC-115 | I | NCT01353625 | Celgene Corporation | mTOR | 144 |
| Sorafenib and Irinotecan | I | NCT01518413 | Children’s Research Institute |
VEGFR | 24 |
| Pazopanib | II | NCT01956669 | GlaxoSmithKline | VEGFR | 154 |
| Alisertib | II | NCT01154816 | Children’s Research Institute |
Aurora A | 228 |
| BMN-673 and temozolomide | I/II | NCT02116777 | National Cancer Institute |
PARP | 172 |
| BMN 673 | I | NCT01286987 | BioMarin Pharmaceutical |
PARP | 85 |
| Olaparib | II | NCT01583543 | Massachusetts General Hospital |
PARP | 24 |
| Olaparib and Temozolomide | I | NCT01858168 | Massachusetts General Hospital |
PARP | 34 |
| Niraparib and Temozolomide | I | NCT02044120 | Sarcoma Alliance for Research through Collaboration |
PARP | 30 |
| RO4929097 | I/II | NCT01154452 | National Cancer Institute |
SMO; γ secretase |
120 |
| humanized anti-GD2 antibody | I | NCT00743496 | St. Jude Children’s Research Hospital |
GD2 | 75 |
|
T cells expressing an anti-GD2 chimeric antigen receptor |
I | NCT02107963 | National Cancer Institute |
GD2 | 72 |
| Iodine I 131 monoclonal antibody 3F8 | II | NCT00445965 | Memorial Sloan- Kettering Cancer Center |
GD2 | 77 |
| Mithramycin | I/II | NCT01610570 | National Cancer Institute |
EWS-FLI1 | 44 |